3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
9
Unknown
5
Terminated
3
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Plasma cell
2
Gynecologic
2
Tumor-Agnostic
1
Thoracic
1
Myeloid
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Psychological Well-Being
1
Motor Activity
1
Lung Neoplasms
1
Esophageal Neoplasms
1
Interventions
Oxaliplatin
197
Bevacizumab
162
Fluorouracil
155
Capecitabine
137
Gemcitabine
133
Leucovorin
112
pembrolizumab
99
Cisplatin
93
Drug Therapy
89
Irinotecan
81
Radiotherapy
73
sintilimab
70
durvalumab
65
130-nm albumin-bound paclitaxel
65
Paclitaxel
64
Specimen Handling
62
Cetuximab
61
lenvatinib
59
tislelizumab
58
Nivolumab
55
Magnetic Resonance Spectroscopy
55
Folfox protocol
55
Blood Specimen Collection
52
atezolizumab
48
Biopsy
46
Surgical Procedures, Operative
40
Taxes
38
Albumin-Bound Paclitaxel
38
Immune Checkpoint Inhibitors
37
HMPL-013
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Curcumin
×
Gastrointestinal
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled